{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:01:10Z","timestamp":1792195270784,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000774","name":"United States Department of Defense | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1930447"],"award-info":[{"award-number":["HDTRA1930447"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Department of Health & Human Services | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["MCMi OCET 2022-1747"],"award-info":[{"award-number":["MCMi OCET 2022-1747"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Limited knowledge exists on the quality of polyclonal antibody responses generated following Marburg virus (MARV) infection and its evolution in survivors. In this study, we evaluate MARV proteome-wide antibody repertoire longitudinally in convalescent phase approximately every six months for five years following MARV infection in ten human survivors. Differential kinetics were observed for IgM vs IgG vs IgA epitope diversity, antibody binding, antibody affinity maturation and Fc-receptor interaction to MARV proteins. Durability of MARV-neutralizing antibodies is low in survivors. MARV infection induces a diverse epitope repertoire with predominance against GP, VP40, VP30 and VP24 that persisted up to 5 years post-exposure. However, the IgM and IgA repertoire declines over time. Within MARV-GP, IgG recognize antigenic sites predominantly in the amino-terminus, wing domain and GP2-heptad repeat. Interestingly, MARV infection generates robust durable Fc\u0263RI, Fc\u0263RIIA and Fc\u0263RIIIA IgG-Fc receptor interactions. Immunization with immunodominant MARV epitopes reveals conserved wing region between GP1 and GP2, induces neutralizing antibodies against MARV. These findings demonstrate that MARV infection generates a diverse, long-lasting, non-neutralizing, IgG antibody repertoire that perturbs disease by Fc\u0263R activity. This information, along with discovery of neutralizing immunogen in wing domain, could aid in development of effective therapeutics and vaccines against Marburg virus.<\/jats:p>","DOI":"10.1038\/s41467-024-51021-5","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:28:58Z","timestamp":1726662538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-7965","authenticated-orcid":false,"given":"Surender","family":"Khurana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Grubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Cluff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5443-8997","authenticated-orcid":false,"given":"JungHyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Kuehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Zak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Dye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius J.","family":"Lutwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"51021_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/d41586-023-00468-5","volume":"614","author":"E Callaway","year":"2023","unstructured":"Callaway, E. Marburg virus outbreak: researchers race to test vaccines. Nature 614, 603 (2023).","journal-title":"Nature"},{"key":"51021_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41579-020-0394-z","volume":"18","author":"M Letko","year":"2020","unstructured":"Letko, M., Seifert, S. N., Olival, K. J., Plowright, R. K. & Munster, V. J. Bat-borne virus diversity, spillover and emergence. Nat. Rev. Microbiol. 18, 461\u2013471 (2020).","journal-title":"Nat. Rev. Microbiol."},{"key":"51021_CR3","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.3390\/v13122394","volume":"13","author":"BR Amman","year":"2021","unstructured":"Amman, B. R., Schuh, A. J., Albarino, C. G. & Towner, J. S. Marburg virus persistence on fruit as a plausible route of bat to primate filovirus transmission. Viruses 13, 2394 (2021).","journal-title":"Viruses"},{"key":"51021_CR4","doi-asserted-by":"publisher","first-page":"e0004475","DOI":"10.1371\/journal.pntd.0004475","volume":"10","author":"J Brainard","year":"2016","unstructured":"Brainard, J., Pond, K., Hooper, L., Edmunds, K. & Hunter, P. Presence and persistence of ebola or marburg virus in patients and survivors: a rapid systematic review. PLoS Negl. Trop. Dis. 10, e0004475 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"51021_CR5","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1056\/NEJMoa1511410","volume":"377","author":"GF Deen","year":"2017","unstructured":"Deen, G. F. et al. Ebola RNA persistence in semen of ebola virus disease survivors - final report. N. Engl. J. Med. 377, 1428\u20131437 (2017).","journal-title":"N. Engl. J. Med"},{"key":"51021_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1805435","volume":"380","author":"PIS Group","year":"2019","unstructured":"Group, P. I. S. et al. A longitudinal study of ebola sequelae in liberia. N. Engl. J. Med 380, 924\u2013934 (2019).","journal-title":"N. Engl. J. Med"},{"key":"51021_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.chom.2018.08.003","volume":"24","author":"KM Coffin","year":"2018","unstructured":"Coffin, K. M. et al. Persistent marburg virus infection in the testes of nonhuman primate survivors. Cell Host Microbe 24, 405\u2013416 e403 (2018).","journal-title":"Cell Host Microbe"},{"key":"51021_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22132-0","volume":"12","author":"RW Cross","year":"2021","unstructured":"Cross, R. W. et al. Combination therapy protects macaques against advanced Marburg virus disease. Nat. Commun. 12, 1891 (2021).","journal-title":"Nat. Commun."},{"key":"51021_CR9","doi-asserted-by":"publisher","first-page":"eaai8711","DOI":"10.1126\/scitranslmed.aai8711","volume":"9","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci. Transl. Med. 9, eaai8711 (2017).","journal-title":"Sci. Transl. Med"},{"key":"51021_CR10","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1073\/pnas.1200409109","volume":"109","author":"JM Dye","year":"2012","unstructured":"Dye, J. M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl Acad. Sci. USA 109, 5034\u20135039 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"51021_CR11","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1084\/jem.20170161","volume":"214","author":"SW Stonier","year":"2017","unstructured":"Stonier, S. W. et al. Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. J. Exp. Med. 214, 2563\u20132572 (2017).","journal-title":"J. Exp. Med"},{"key":"51021_CR12","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1093\/infdis\/jiv351","volume":"212","author":"B Knust","year":"2015","unstructured":"Knust, B. et al. Multidistrict outbreak of Marburg virus disease-Uganda, 2012. J. Infect. Dis. 212, S119\u2013S128 (2015). Suppl 2.","journal-title":"J. Infect. Dis."},{"key":"51021_CR13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/nm.4201","volume":"22","author":"S Khurana","year":"2016","unstructured":"Khurana, S. et al. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat. Med. 22, 1439\u20131447 (2016).","journal-title":"Nat. Med"},{"key":"51021_CR14","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41590-021-01051-8","volume":"22","author":"S Ravichandran","year":"2021","unstructured":"Ravichandran, S. et al. SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19. Nat. Immunol. 22, 1452\u20131464 (2021).","journal-title":"Nat. Immunol."},{"key":"51021_CR15","doi-asserted-by":"publisher","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","volume":"3","author":"S Khurana","year":"2011","unstructured":"Khurana, S. et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3, 85ra48 (2011).","journal-title":"Sci. Transl. Med"},{"key":"51021_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11296-5","volume":"10","author":"S Khurana","year":"2019","unstructured":"Khurana, S. et al. Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans. Nat. Commun. 10, 3338 (2019).","journal-title":"Nat. Commun."},{"key":"51021_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.chom.2020.01.001","volume":"27","author":"S Khurana","year":"2020","unstructured":"Khurana, S. et al. Longitudinal human antibody repertoire against complete viral proteome from ebola virus survivor reveals protective sites for vaccine design. Cell Host Microbe 27, 262\u2013276 e264 (2020).","journal-title":"Cell Host Microbe"},{"key":"51021_CR18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41392-021-00759-1","volume":"6","author":"Y Yu","year":"2021","unstructured":"Yu, Y. et al. Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. Signal Transduct. Target Ther. 6, 346 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"51021_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.chom.2018.07.009","volume":"24","author":"BM Gunn","year":"2018","unstructured":"Gunn, B. M. et al. A role for fc function in therapeutic monoclonal antibody-mediated protection against ebola virus. Cell Host Microbe 24, 221\u2013233 e225 (2018).","journal-title":"Cell Host Microbe"},{"key":"51021_CR20","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.4049\/jimmunol.166.12.7381","volume":"166","author":"VC Huber","year":"2001","unstructured":"Huber, V. C., Lynch, J. M., Bucher, D. J., Le, J. & Metzger, D. W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166, 7381\u20137388 (2001).","journal-title":"J. Immunol."},{"key":"51021_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46\u201361 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"51021_CR22","doi-asserted-by":"crossref","unstructured":"Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z. & Anzaghe, M. The role of Fc receptors on the effectiveness of therapeutic monoclonal antibodies. Int. J. Mol. Sci. 22, 8947\u20138971 (2021).","DOI":"10.3390\/ijms22168947"},{"key":"51021_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12334","volume":"268","author":"JF Swisher","year":"2015","unstructured":"Swisher, J. F. & Feldman, G. M. The many faces of FcgammaRI: implications for therapeutic antibody function. Immunol. Rev. 268, 160\u2013174 (2015).","journal-title":"Immunol. Rev."},{"key":"51021_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn, F. & Ravetch, J. V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34\u201347 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"51021_CR25","doi-asserted-by":"publisher","first-page":"S318","DOI":"10.1093\/infdis\/jiy424","volume":"218","author":"E Mittler","year":"2018","unstructured":"Mittler, E., Schudt, G., Halwe, S., Rohde, C. & Becker, S. A fluorescently labeled Marburg virus glycoprotein as a new tool to study viral transport and assembly. J. Infect. Dis. 218, S318\u2013S326 (2018).","journal-title":"J. Infect. Dis."},{"key":"51021_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi6533","volume":"7","author":"S Ravichandran","year":"2021","unstructured":"Ravichandran, S. et al. Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2-infected individuals reveal unlinked immune signatures. Sci. Adv. 7, eabi6533 (2021).","journal-title":"Sci. Adv."},{"key":"51021_CR27","doi-asserted-by":"publisher","first-page":"eabf2467","DOI":"10.1126\/sciadv.abf2467","volume":"7","author":"S Ravichandran","year":"2021","unstructured":"Ravichandran, S. et al. Longitudinal antibody repertoire in \u201cmild\u201d versus \u201csevere\u201d COVID-19 patients reveals immune markers associated with disease severity and resolution. Sci. Adv. 7, eabf2467 (2021).","journal-title":"Sci. Adv."},{"key":"51021_CR28","doi-asserted-by":"publisher","first-page":"e1000049","DOI":"10.1371\/journal.pmed.1000049","volume":"6","author":"S Khurana","year":"2009","unstructured":"Khurana, S. et al. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 6, e1000049 (2009).","journal-title":"PLoS Med"},{"key":"51021_CR29","doi-asserted-by":"publisher","first-page":"15ra15","DOI":"10.1126\/scitranslmed.3000624","volume":"2","author":"S Khurana","year":"2010","unstructured":"Khurana, S. et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2, 15ra15 (2010).","journal-title":"Sci. Transl. Med"},{"key":"51021_CR30","doi-asserted-by":"publisher","first-page":"e1005554","DOI":"10.1371\/journal.ppat.1005554","volume":"12","author":"S Fuentes","year":"2016","unstructured":"Fuentes, S., Coyle, E. M., Beeler, J., Golding, H. & Khurana, S. Antigenic fingerprinting following primary RSV infection in young children identifies novel antigenic sites and reveals unlinked evolution of human antibody repertoires to fusion and attachment glycoproteins. PLoS Pathog. 12, e1005554 (2016).","journal-title":"PLoS Pathog."},{"key":"51021_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09914-3","volume":"10","author":"S Ravichandran","year":"2019","unstructured":"Ravichandran, S. et al. Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome. Nat. Commun. 10, 1943 (2019).","journal-title":"Nat. Commun."},{"key":"51021_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi8631","volume":"13","author":"C Atyeo","year":"2021","unstructured":"Atyeo, C. et al. COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women. Sci. Transl. Med. 13, eabi8631 (2021).","journal-title":"Sci. Transl. Med"},{"key":"51021_CR33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.chom.2020.03.025","volume":"27","author":"PA Ilinykh","year":"2020","unstructured":"Ilinykh, P. A. et al. Non-neutralizing antibodies from a Marburg infection survivor mediate protection by fc-effector functions and by enhancing efficacy of other antibodies. Cell Host Microbe 27, 976\u2013991 e911 (2020).","journal-title":"Cell Host Microbe"},{"key":"51021_CR34","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(22)02400-X","volume":"401","author":"MJ Hamer","year":"2023","unstructured":"Hamer, M. J. et al. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. Lancet 401, 294\u2013302 (2023).","journal-title":"Lancet"},{"key":"51021_CR35","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","volume":"160","author":"AI Flyak","year":"2015","unstructured":"Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893\u2013903 (2015).","journal-title":"Cell"},{"key":"51021_CR36","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.celrep.2016.04.026","volume":"15","author":"KA Howell","year":"2016","unstructured":"Howell, K. A. et al. Antibody treatment of ebola and sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site. Cell Rep. 15, 1514\u20131526 (2016).","journal-title":"Cell Rep."},{"key":"51021_CR37","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.cell.2022.02.023","volume":"185","author":"JC Milligan","year":"2022","unstructured":"Milligan, J. C. et al. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell 185, 995\u20131007 e1018 (2022).","journal-title":"Cell"},{"key":"51021_CR38","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.aad6117","volume":"351","author":"J Misasi","year":"2016","unstructured":"Misasi, J. et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351, 1343\u20131346 (2016).","journal-title":"Science"},{"key":"51021_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature13777","volume":"514","author":"X Qiu","year":"2014","unstructured":"Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47\u201353 (2014).","journal-title":"Nature"},{"key":"51021_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.chom.2018.12.004","volume":"25","author":"AZ Wec","year":"2019","unstructured":"Wec, A. Z. et al. Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection. Cell Host Microbe 25, 39\u201348 e35 (2019).","journal-title":"Cell Host Microbe"},{"key":"51021_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41594-019-0191-4","volume":"26","author":"BR West","year":"2019","unstructured":"West, B. R. et al. Structural basis of broad ebolavirus neutralization by a human survivor antibody. Nat. Struct. Mol. Biol. 26, 204\u2013212 (2019).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"51021_CR42","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","volume":"174","author":"EO Saphire","year":"2018","unstructured":"Saphire, E. O. et al. Systematic analysis of monoclonal antibodies against ebola virus gp defines features that contribute to protection. Cell 174, 938\u2013952 e913 (2018).","journal-title":"Cell"},{"key":"51021_CR43","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/pathogens11030374","volume":"11","author":"X Yu","year":"2022","unstructured":"Yu, X. & Saphire, E. O. Development and structural analysis of antibody therapeutics for filoviruses. Pathogens 11, 374 (2022).","journal-title":"Pathogens"},{"key":"51021_CR44","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2015.01.041","volume":"160","author":"T Hashiguchi","year":"2015","unstructured":"Hashiguchi, T. et al. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 160, 904\u2013912 (2015).","journal-title":"Cell"},{"key":"51021_CR45","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786\u2013790 (2005).","journal-title":"Nat. Med"},{"key":"51021_CR46","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.1128\/JVI.00959-06","volume":"80","author":"KM Daddario-DiCaprio","year":"2006","unstructured":"Daddario-DiCaprio, K. M. et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J. Virol. 80, 9659\u20139666 (2006).","journal-title":"J. Virol."},{"key":"51021_CR47","doi-asserted-by":"publisher","first-page":"e94355","DOI":"10.1371\/journal.pone.0094355","volume":"9","author":"CE Mire","year":"2014","unstructured":"Mire, C. E. et al. Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates. PLoS One 9, e94355 (2014).","journal-title":"PLoS One"},{"key":"51021_CR48","doi-asserted-by":"publisher","first-page":"e1005016","DOI":"10.1371\/journal.ppat.1005016","volume":"11","author":"ML Fusco","year":"2015","unstructured":"Fusco, M. L. et al. Protective mAbs and cross-reactive mabs raised by immunization with engineered Marburg virus GPs. PLoS Pathog. 11, e1005016 (2015).","journal-title":"PLoS Pathog."},{"key":"51021_CR49","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nsmb.2150","volume":"18","author":"JM Dias","year":"2011","unstructured":"Dias, J. M. et al. A shared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 18, 1424\u20131427 (2011).","journal-title":"Nat. Struct. Mol. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51021-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51021-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51021-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T11:04:38Z","timestamp":1726743878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51021-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51021"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51021-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K. is inventor on a patent application describing the GFPDL technology reported in this study. The rest of the authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8133"}}